

Ranfoli SR 500

Ranfoli SR 500 Tablet

Composition:

Each film-coated sustained-release tablet contains:

- **Ranolazine** 500 mg (Extended Release)
- **Excipients** q.s.

Description:

Ranfoli SR 500 Tablet contains Ranolazine, an anti-anginal agent used in the management of chronic stable angina. It works by improving myocardial energy efficiency without significantly affecting heart rate or blood pressure. It is particularly useful in patients who remain symptomatic despite conventional therapy.

Pharmacological Action:

Ranolazine inhibits the late phase of the inward sodium current in cardiac myocytes during repolarization, leading to a reduction in intracellular calcium and improved myocardial relaxation. This reduces myocardial oxygen consumption and improves exercise tolerance.

Indications:

- Chronic stable angina
- Microvascular angina (as adjunct therapy)

Dosage and Administration:

- Recommended starting dose: 500 mg twice daily
- Dose may be titrated to 1000 mg twice daily based on clinical response
- Tablet should be swallowed whole and not crushed or chewed
- Can be taken with or without food

Contraindications:

- Hypersensitivity to Ranolazine or any component of the formulation
- Clinically significant hepatic impairment
- Concurrent use with strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin)

Warnings and Precautions:

- Use with caution in patients with renal impairment
- May prolong the QT interval; caution in patients with predisposing conditions
- Not indicated for the treatment of acute angina attacks
- Avoid use with grapefruit juice

Adverse Effects:

- Common: Dizziness, headache, constipation, nausea
- Rare: QT prolongation, palpitations, hypotension

Drug Interactions:

- Avoid use with strong CYP3A4 inhibitors (e.g., itraconazole)
- Use with caution with moderate CYP3A4 inhibitors and P-gp substrates
- May increase serum levels of digoxin, simvastatin, and metformin

Storage Conditions:

- Store below 30°C in a dry place
- Protect from moisture and direct sunlight
- Keep out of reach of children

Conclusion:

Ranfoli SR 500 Tablet is a well-tolerated and effective therapy for chronic stable angina, particularly beneficial in patients who do not respond adequately to first-line anti-anginal treatments. Its sustained-release formulation allows for convenient twice-daily dosing and steady plasma levels.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for